The European Patent Office granted a patent covering ZyVersa Therapeutics’ (NASDAQ:ZVSA) Phase 2a-ready Cholesterol Efflux Mediator VAR 200 for use in diabetic nephropathy/diabetic kidney disease.
“Approval of this patent claiming our Cholesterol Efflux Mediator VAR 200 for use in treating diabetic kidney disease speaks to the innovative and important research conducted by Dr. Alesssia Fornoni and her team involving removal of excess cholesterol and lipids that damage the kidneys’ filtration system,” Stephen Glover, co-founder, chairman, CEO, and president of ZyVersa, said in a statement.
Dr. Fornoni is Katz Professor of Medicine, Chief, Katz Family Division of Nephrology & Hypertension, and Director of Peggy & Harold Katz Drug Discovery Center at the University of Miami.
“Strengthening our intellectual property portfolio for VAR 200 and expanding our patent protection and exclusive rights into additional geographic regions will further enable ZyVersa to increase shareholder value as VAR 200 advances into clinical trials, which are planned for initiation in the fourth quarter of this year,” Mr. Glover said.
